Abstract Number: 32

Statins reduce disease recurrence in patients with ulcerated primary melanoma

L. A. von Schuckmann1,2, K. Khosrotehrani3, R. Ghiasvand4, M. C. B. Hughes2, J. C. van der Pols5, M. Malt2, M. Smithers6, A. C. Green2,7

Meeting: 2021 Dermcoll

Session Information

Date: -

Session Title: Free Papers

Session Time: -

Background: Statins may restrict cellular functions required for melanoma growth and metastasis. We exam- ined whether long-term statin use commenced before diagnosis of the primary is associated with reduced risk of melanoma recurrence.

Patients and methods: We prospectively followed a cohort of patients newly diagnosed between 2010 and 2014 with localised tumour-stage T1b to T4b melanoma in Queensland, Australia. We used Cox-regression analyses to examine associations between long-term statin use and melanoma recurrence for the entire cohort, and then sepa- rately by sex and by presence of ulceration due to evidence of effect modification.

Results: Amongst 700 patients diagnosed with stage T1b to T4b primary melanoma (mean age 62, 59% male, 28% with ulcerated tumors), 94 patients (13%) developed mela- noma recurrence within 2 years. Long-term statin users (n = 204, 29%) had a significantly lower risk of disease recurrence compared to non-users (Adjusted hazard ratio (HRadj) 0.55, 95% Confidence Interval (CI) 0.32–0.97) regardless of statin subtype or potency. Compared to non- statin users, risk of recurrence was significantly decreased in male statin-users (HRadj 0.39, 95% CI: 0.19–0.79) but not female statin users (HRadj 0.82, 95% CI: 0.29–2.27) and in statin-users with ulcerated (HRadj 0.17, 95% CI: 0.05–0.52) but not non-ulcerated (HRadj 0.91, 95% CI: 0.46–1.81) pri- mary melanoma.

Conclusion: Statins commenced before melanoma diagno- sis, may reduce the risk of melanoma recurrence, espe- cially in males and those with ulcerated tumors. Clinical trial evaluation of the potential role of statins in improving the prognosis of high-risk melanoma is warranted.